PRP Joint Therapy Solutions in Salem, OR

What I’d check before adding prp joint therapy here

Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 11.7% of adults in Salem have diagnosed diabetes — 0.3 points below the U.S. 12% figure. 11.6% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick prp joint therapy against that mix.

Where Salem programs actually stall

• Adult arthritis here is 26.3% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 11.6% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Oregon.
• Oregon Health Authority publishes state chronic-disease context that clinics can cite in patient education. Pair that with FDA 361 labeling — homologous use, minimal manipulation — so marketing does not outrun the product's actual regulatory lane.
• First Coast (Florida) is the only single-state MAC; every other state shares a contractor with neighbors. Oregon is JF — copy-pasting a Florida LCD packet here is a denial pattern we still see.

Uninsured mix and Medicare CTPs in the same building

JF reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Salem is 11.7% or not. PLACES is planning data. The LCD is the claim.

How we’d stand this up in clinic